The Use of Busulphan As Compared to Melphalan in Combination with Fludarabine in the Reduced Intensity Conditioning Improves Overall Survival in Patients with Lymphoma

被引：0

作者：

Kekre, Natasha ^{[1
]}

Marquez-Malaver, Francisco J. ^{[2
]}

Caballero, Dolores ^{[3
]}

Pinana, J. I. ^{[4
]}

Esquirol, Albert ^{[5
]}

Soiffer, Robert J. ^{[6
]}

Cabrero, Monica ^{[7
]}

Terol, M. J. ^{[4
]}

Martino, Rodrigo ^{[8
]}

Antin, Joseph H. ^{[9
]}

Lopez Corral, L. ^{[7
]}

Solano, Carlos ^{[10
]}

Armand, Philippe ^{[1
]}

Perez-Simon, Jose A. ^{[11
]}

机构：

[1] Dana Farber Canc Inst, Boston, MA 02115 USA

[2] Univ Seville, CSIC, Hosp Univ Virgen Rocio, Dept Hematol,Inst Biomed Sevilla IBIS, Seville, Spain

[3] Hosp Univ Salamanca, Salamanca, Spain

[4] Hosp Clin Univ, Dept Hematol Oncol, Valencia, Spain

[5] Hosp Santa Creu & Sant Pau, Jose Carreras Leukemia Res Inst, Clin Hematol Serv, Barcelona, Spain

[6] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA

[7] Univ Salamanca, Inst Biosanitario Salamanca IBSAL, Univ Hosp, Hematol Serv, E-37008 Salamanca, Spain

[8] Hosp Santa Creu & Sant Pau, Barcelona, Spain

[9] Childrens Hosp, Dana Farber Canc Inst, Massachusetts Gen, Boston, MA 02115 USA

[10] Hosp Clin Univ La Fe, Dept Hematol, Valencia, Spain

[11] Hosp Univ Virgen del Rocio, Dept Hematol, Seville, Spain

来源：

BLOOD | 2015年 / 126卷 / 23期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：3

共 50 条

[31] Reduced-intensity conditioning regimen with fludarabine/melphalan versus sequential melphalan, fludarabine and total body irradiation conditioning in acute myeloid leukemia patients with active leukemia or measurable residual disease
Lindner, S.
Lohmeyer, J.
Schlipfenbacher, V.
Nguyen, N. T. T.
Weber, B.
Toenges, R.
Riemann, J.
Pfeifer, H.
Ajib, S.
Berg, T.
Lang, F.
Martin, H.
Serve, H.
Bug, G.
ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 282 - 282
[32] The use of fludarabine based reduced intensity conditioning for the treatment of patients with Fanconi's anemia
Slavin, S
Bitan, M
Aker, M
Resnik, I
Shapira, MY
Or, R
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2004, 10 (02) : 75 - 75
[33] Reduced-intensity conditioning does not improve survival compared to standard conditioning for patients with myeloma
Crawley, C
Iacobelli, S
Björkstrand, B
Apperley, J
Niederwieser, D
Gahrton, G
BONE MARROW TRANSPLANTATION, 2005, 35 : S48 - S48
[34] Hematopoietic cell transplantation with reduced intensity conditioning regimen using fludarabine/busulfan and fludarabine/melphalan for primary immunodeficiency diseases
Nishimura, Akira
Aoki, Yuki
Ishiwata, Yasuyoshi
Inoue, Maiko
Ichimura, Takuya
Ueyama, Junichi
Matsumoto, Kazuaki
Inoue, Kento
Hiroki, Haruka
Ono, Shintaro
Okano, Tsubasa
Tanaka, Mari
Miyamoto, Satoshi
Ashiarai, Miho
Miyawaki, Reiji
Yamagishi, Chika
Tezuka, Mari
Okawa, Teppei
Hoshino, Akihiro
Endo, Akifumi
Yasuhara, Masato
Kamiya, Takahiro
Mitsuiki, Noriko
Ono, Toshiaki
Yanagimachi, Masakatsu
Isoda, Takeshi
Tomizawa, Daisuke
Nagasawa, Masayuki
Kajiwara, Michiko
Takagi, Masatoshi
Mizutani, Shuki
Kanegane, Hirokazu
Imai, Kohsuke
Morio, Tomohiro
BONE MARROW TRANSPLANTATION, 2019, 54 : 390 - 391
[35] Choosing a reduced intensity conditioning, fludarabine melphalan versus fludarabine busulfan: A meta-analysis and systematic review.
Jain, Tania
Sonbol, Mohamad Bassam
Firwana, Belal
Almader-Douglas, Diana
Palmer, Jeanne
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[36] Reduced-intensity conditioning with fludarabine/busulfan versus fludarabine/low-dose melphalan in patients with non-Hodgkin lymphoma undergoing allogeneic haematopoietic stem cell transplantation
Kamijo, Kimimori
Shimomura, Yoshimitsu
Kim, Sung-Won
Ohigashi, Hiroyuki
Ishikawa, Jun
Eto, Tetsuya
Hiramoto, Nobuhiro
Mizuno, Ishikazu
Iida, Shinsuke
Ueda, Yasunori
Matsuoka, Ken-ichi
Yakushijin, Kimikazu
Mori, Yasuo
Onizuka, Makoto
Fukuda, Takahiro
Atsuta, Yoshiko
Kako, Shinichi
BRITISH JOURNAL OF HAEMATOLOGY, 2024, 205 (03) : 1097 - 1107
[37] A fludarabine and melphalan reduced-intensity conditioning regimen for HSCT in fifteen chronic granulomatous disease patients and a literature review
Vaezi, Mohammad
Souri, Maryam
Setarehdan, Seyed Amin
Hamidieh, Amir Ali
Fazlollahi, Mohammad Reza
Pourpak, Zahra
Badalzadeh, Mohsen
Tajik, Shaghayegh
Mahdaviani, Seyed Alireza
Alimoghaddam, Kamran
Ghavamzadeh, Ardeshir
ANNALS OF HEMATOLOGY, 2022, 101 (04) : 869 - 880
[38] Reduced-Intensity Conditioning with Fludarabine/Busulfan Versus Fludarabine/Low-Dose Melphalan in Patients with Non-Hodgkin Lymphoma Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
Kamijo, Kimimori
Shimomura, Yoshimitsu
Kim, Sung-Won
Ara, Takahide
Ishikawa, Jun
Eto, Tetsuya
Hiramoto, Nobuhiro
Mizuno, Ishikazu
Kusumoto, Shigeru
Ueda, Yasunori
Matsuoka, Ken-ichi
Onizuka, Makoto
Fukuda, Takahiro
Atsuta, Yoshiko
Kondo, Eisei
BLOOD, 2022, 140 : 2393 - 2394
[39] A fludarabine and melphalan reduced-intensity conditioning regimen for HSCT in fifteen chronic granulomatous disease patients and a literature review
Mohammad Vaezi
Maryam Souri
Seyed Amin Setarehdan
Amir Ali Hamidieh
Mohammad Reza Fazlollahi
Zahra Pourpak
Mohsen Badalzadeh
Shaghayegh Tajik
Seyed Alireza Mahdaviani
Kamran Alimoghaddam
Ardeshir Ghavamzadeh
Annals of Hematology, 2022, 101 : 869 - 880
[40] Cord blood transplantation with a reduced-intensity conditioning regimen using fludarabine and melphalan for adult T-cell leukemia/lymphoma
Nobuaki Nakano
Yoshifusa Takatsuka
Ayumu Kubota
Masahito Tokunaga
Takayoshi Miyazono
Tomohisa Tabuchi
Jun Odawara
Mayumi Tokunaga
Torahiko Makino
Shogo Takeuchi
Yoshikiyo Ito
Atae Utsunomiya
International Journal of Hematology, 2021, 113 : 861 - 871

← 1 2 3 4 5 →